Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines

Schizophrenia Research

Volumn 121, Issue 1-3, 2010, Pages 107-117

  Kuepper, Rebecca ^a   Morrison, Paul D ^c   van Os, Jim ^a,c   Murray, Robin M ^c   Kenis, Gunter ^a   Henquet, Cécile ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Mondriaan Zorggroep   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis; Dopamine; Endocannabinoid system; Psychosis; THC

Indexed keywords

CANNABIS; DOPAMINE; DRONABINOL; ENDOCANNABINOID;

BRAIN LEVEL; CANNABIS SMOKING; CORPUS STRIATUM; DELUSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; HALLUCINATION; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SENSITIZATION; ANIMAL; BRAIN CORTEX; CANNABIS ADDICTION; COMPLICATION; DRUG EFFECTS; METABOLISM; NERVE TRACT; PSYCHOTIC DISORDERS;

ANIMALS; CANNABIS; CEREBRAL CORTEX; DOPAMINE; HUMANS; MARIJUANA ABUSE; NEURAL PATHWAYS; PSYCHOTIC DISORDERS; TETRAHYDROCANNABINOL; DRONABINOL;

EID: 77955054913     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.05.031     Document Type: Review

References (164)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2004, 7(Suppl 1):S1-S5.
2. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003, 9:404-416.
3. Abi-Dargham A., Rodenhiser J., Printz D., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8104-8109.
4. Abi-Dargham A., Mawlawi O., Lombardo I., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. Journal of Neuroscience 2002, 22:3708-3719.
5. Abler B., Walter H., Erk S., et al. Prediction error as a linear function of reward probability is coded in human nucleus accumbens. Neuroimage 2006, 31:790-795.
6. Akhondzadeh S., Shasavand E., Jamilian H., et al. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics 2000, 25:131-137.
7. Akhondzadeh S., Safarcherati A., Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro-psychopharmacology & Biological Psychiatry 2005, 29:253-259.
8. Akil M., Kolachana B.S., Rothmond D.A., et al. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. Journal of Neuroscience 2003, 23:2008-2013.
9. Andersen M.B., Fuxe K., Werge T., et al. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behavioural Pharmacology 2002, 13:639-644.
10. Arnone D., Barrick T.R., Chengappa S., et al. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008, 41:1067-1074.
11. Arnsten A.F.T. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cerebral Cortex 2007, 17:6-15.
12. Arseneault L., Cannon M., Poulton R., et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (Clinical research ed) 2002, 325:1212-1213.
13. Bach M.E., Simpson E.H., Kahn L., et al. Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16027-16032.
14. Bayer H.M., Glimcher P.W. Midbrain dopamine neurons encode a quantitative reward prediction error signal. Neuron 2005, 47:129-141.
15. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Research. Brain Research Reviews 1998, 28:309-369.
16. Bhattacharyya S., Morrison P.D., Fusar-Poli P., et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35(3):764-774.
17. Bilder R.M., Volavka J., Lachman H.M., et al. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29:1943-1961.
18. Boileau I., Dagher A., Leyton M., et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Archives of General Psychiatry 2006, 63:1386-1395.
19. Bossong M.G., van Berckel B.N., Boellaard R., et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
20. Broderick P., Benjamin A.B. Caffeine and psychiatric symptoms: a review. The Journal of the Oklahoma State Medical Association 2004, 97:538-542.
21. Brunstein M.G., Ghisolfi E.S., Ramos F.L., et al. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. The Journal of Clinical Psychiatry 2005, 66:213-219.
22. Cadoni C., Pisanu A., Solinas M., et al. Behavioural sensitization after repeated exposure to delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 2001, 158:259-266.
23. Cadoni C., Valentini V., Di Chiara G. Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. Journal of Neurochemistry 2008, 106:1586-1593.
24. Calabresi P., Picconi B., Tozzi A., et al. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences 2007, 30:211-219.
25. Carlsson A. Does dopamine play a role in schizophrenia?. Psychological Medicine 1977, 7:583-597.
26. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. The American Journal of Psychiatry 1978, 135:165-173.
27. Carlsson A. The Neurochemical Circuitry of Schizophrenia. Pharmacopsychiatry 2006, 39:10-14.
28. Carlsson A., Carlsson M.L. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues in Clinical Neuroscience 2006, 8:137-142.
29. Caspi A., Moffitt T.E., Cannon M., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 2005, 57:1117-1127.
30. Cheer J.F., Wassum K.M., Heien M.L., et al. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. Journal of Neuroscience 2004, 24:4393-4400.
31. Cheer J.F., Wassum K.M., Sombers L.A., et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. Journal of Neuroscience 2007, 27:791-795.
32. Chen J., Paredes W., Lowinson J.H., et al. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. European Journal of Pharmacology 1990, 190:259-262.
33. Chen J.C., Liang K.W., Huang Y.K., et al. Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine. Life Sciences 2001, 68:973-983.
34. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuroscience 2006, 29:37-76.
35. Chiang Y.C., Chen J.C. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry 2007, 103(6):2505-2517.
36. Collip D., Myin-Germeys I., Van Os J. Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia?. Schizophrenia Bulletin 2008, 34:220-225.
37. Corbille A.G., Valjent E., Marsicano G., et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. Journal of Neuroscience 2007, 27:6937-6947.
38. Cougnard A., Marcelis M., Myin-Germeys I., et al. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychological Medicine 2007, 37:513-527.
39. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. British Journal of Psychiatry 2004, 185:196-204.
40. D'Ardenne K., McClure S.M., Nystrom L.E., et al. BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. Science (New York, N.Y.) 2008, 319:1264-1267.
41. de Jong J.G., Wasilewski M., van der Vegt B.J., et al. A single social defeat induces short-lasting behavioral sensitization to amphetamine. Physiology and Behavior 2005, 83:805-811.
42. Dean B., Sundram S., Bradbury R., et al. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
43. DeLisi L.E. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?. Current Opinion in Psychiatry 2008, 21:140-150.
44. Delisi L.E., Bertisch H.C., Szulc K.U., et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduction Journal 2006, 3:17.
45. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. Journal of Neural Transmission 1992, 36:61-89.
46. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Research 1990, 521:311-315.
47. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949. (New York, N.Y.).
48. Di Forti M., Lappin J.M., Murray R.M. Risk factors for schizophrenia-all roads lead to dopamine. European Neuropsychopharmacology 2007, 17(Suppl 2):101-S107.
49. Dickerson F.B., Stallings C.R., Origoni A.E., et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research 2009, 109:66-69.
50. Dominguez M.D., Wichers M., Lieb R., et al. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophrenia Bulletin 2009, May 21. [Epub ahead of print].
51. Drew M.R., Simpson E.H., Kellendonk C., et al. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. Journal of Neuroscience 2007, 27:7731-7739.
52. D'Souza D.C., Abi-Saab W.M., Madonick S., et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
53. D'Souza D.C., Braley G., Blaise R., et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198:587-603.
54. Egerton A., Allison C., Brett R.R., et al. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neuroscience and Biobehavioral Reviews 2006, 30:680-695.
55. Erritzoe D., Talbot P., Frankle W.G., et al. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clinics of North America 2003, 13:817-832.
56. Filip M., Golda A., Zaniewska M., et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacological Reports 2006, 58:806-819.
57. Floresco S.B., West A.R., Ash B., et al. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nature Neuroscience 2003, 6:968-973.
58. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997, 8:649-652.
59. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews 2003, 83:1017-1066.
60. Gerdeman G.L., Ronesi J., Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience 2002, 5:446-451.
61. Goldman-Rakic P.S. The "psychic" neuron of the cerebral cortex. Annals of the New York Academy of Sciences 1999, 868:13-26.
62. Goldman-Rakic P.S., Castner S.A., Svensson T.H., et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004, 174:3-16.
63. Goto Y., Otani S., Grace A.A. The yin and yang of dopamine release: a new perspective. Neuropharmacology 2007, 53:583-587.
64. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. International Review of Neurobiology 2007, 78:1-39.
65. Harley M., Kelleher I., Clarke M., et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychological Medicine 2009, 1-8.
66. Hedges D.W., Woon F.L., Hoopes S.P. Caffeine-induced psychosis. CNS Spectrums 2009, 14:127-129.
67. Henquet C., Krabbendam L., Spauwen J., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (Clinical research ed) 2005, 330:11.
68. Henquet C., Murray R., Linszen D., et al. The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 2005, 31:608-612.
69. Henquet C., Rosa A., Krabbendam L., et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
70. Henquet C., Di Forti M., Morrison P., et al. Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 2008, 34:1111-1121.
71. Henquet C., Kuepper R., Konings M., et al. Do cannabis and urbanicity interact in causing psychosis?. Schizophrenia Bulletin 2009, 35:87.
72. Herkenham M., Lynn A.B., Little M.D., et al. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:1932-1936.
73. Hietala J., Syvalahti E., Vuorio K., et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Archives of General Psychiatry 1994, 51:116-123.
74. Hilario M.R., Clouse E., Yin H.H., et al. Endocannabinoid signaling is critical for habit formation. Frontiers in Integrative Neuroscience 2007, 1:6.
75. Houston J.E., Murphy J., Adamson G., et al. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophrenia Bulletin 2008, 34:580-585.
76. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-The final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
77. Howes O.D., Montgomery A.J., Asselin M.C., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 2009, 66:13-20.
78. Huttunen J., Heinimaa M., Svirskis T., et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biological Psychiatry 2008, 63:114-117.
79. Jensen J., Willeit M., Zipursky R.B., et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008, 33:473-479.
80. Jentsch J.D., Andrusiak E., Tran A., et al. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997, 16:426-432.
81. Jentsch J.D., Verrico C.D., Le D., et al. Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neuroscience Letters 1998, 246:169-172.
82. Juckel G., Schlagenhauf F., Koslowski M., et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
83. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-psychopharmacology & Biological Psychiatry 2003, 27:1081-1090.
84. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 2005, 79:59-68.
85. Kellendonk C., Simpson E.H., Polan H.J., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
86. Kikusui T., Faccidomo S., Miczek K.A. Repeated maternal separation: differences in cocaine-induced behavioral sensitization in adult male and female mice. Psychopharmacology 2005, 178:202-210.
87. Koethe D., Llenos I.C., Dulay J.R., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. Journal of Neural Transmission 2007, 114:1055-1063.
88. Konings M., Henquet C., Maharajh H.D., et al. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica 2008, 118(3):209-213.
89. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. The Journal of Neuroscience 2005, 25:10537-10545.
90. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. Journal of Neuroscience 2005, 25:10537-10545.
91. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
92. Lamarque S., Taghzouti K., Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001, 41:118-129.
93. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. Journal of Psychopharmacology 1999, 13:358-371.
94. Laruelle M., Kegeles L.S., Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of the New York Academy of Science 2003, 1003:138-158.
95. Leweke M., Giuffrida A., Wurster U., et al. Elevated endogenous cannabinoids in schizophrenia. NeuroReport 1999, 10:1665-1669.
96. Leweke M., Schneider U., Radwan M., et al. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacology, Biochemistry and Behavior 2000, 66:175-181.
97. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
98. Liem-Moolenaar M., Te Beek E.T., de Kam M.L., et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. Journal of Psychopharmacology 2010, (Oxford, England).
99. Linszen D., van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Current Opinion in Psychiatry 2007, 20:116-120.
100. Lodge D.J., Grace A.A. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. Journal of Neuroscience 2008, 28:7876-7882.
101. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacology, Biochemistry and Behavior 2005, 81:319-330.
102. Lupica C.R., Riegel A.C. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005, 48:1105-1116.
103. Lynch M.R. Schizophrenia and the D1 receptor: focus on negative symptoms. Progress in Neuro-psychopharmacology & Biological Psychiatry 1992, 16:797-832.
104. MacLean K.I., Littleton J.M. Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. European Journal of Pharmacology 1977, 41:171-182.
105. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends in Neurosciences 2006, 29:225-232.
106. Martinot J.L., Peron-Magnan P., Huret J.D., et al. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. The American Journal of Psychiatry 1990, 147:44-50.
107. Matochik J.A., Eldreth D.A., Cadet J.L., et al. Altered brain tissue composition in heavy marijuana users. Drug and Alcohol Dependence 2005, 77:23-30.
108. Matyas F., Urban G.M., Watanabe M., et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 2008, 54:95-107.
109. McGrath J., Welham J., Scott J., et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 2010, 67(5):440-447.
110. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995, 50:83-90.
111. Melis M., Perra S., Muntoni A.L., et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. Journal of Neuroscience 2004, 24:10707-10715.
112. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 2002, 5:267-271.
113. Mokler D.J., Robinson S.E., Johnson J.H., et al. Neonatal administration of delta-9-tetrahydrocannabinol (THC) alters the neurochemical response to stress in the adult Fischer-344 rat. Neurotoxicology and Teratology 1987, 9:321-327.
114. Moore T.H., Zammit S., Lingford-Hughes A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
115. Morrison P.D., Murray R.M. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophrenia Bulletin 2009, 35:668-674.
116. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. British Medical Journal (Clinical Research Edition) 1987, 295:681-682.
117. Murray R.M., Morrison P.D., Henquet C., et al. Cannabis, the mind and society: the hash realities. Nature Reviews. Neuroscience 2007, 8:885-895.
118. Murray G.K., Corlett P., Clark L., et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular Psychiatry 2008, 13(239):267-276.
119. Murray R.M., Lappin J., Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. European Neuropsychopharmacology 2008, 18(Suppl 3):129-S134.
120. Myin-Germeys I., Delespaul P., van Os J. Behavioural sensitization to daily life stress in psychosis. Psychological Medicine 2005, 35:733-741.
121. Nordstrom A.L., Farde L., Eriksson L., et al. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Research 1995, 61:67-83.
122. O'Daly O., Guillin O., Tsapakis E., et al. Schizophrenia and substance abuse co-morbidity: a role for dopamine sensitization?. Journal of Dual Diagnosis 2005, 1:11-40.
123. Patrick S.L., Thompson T.L., Walker J.M., et al. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus. Brain Research 1991, 538:343-346.
124. Pawlak V., Kerr J.N. Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. Journal of Neuroscience 2008, 28:2435-2446.
125. Pertwee R.G. Cannabinoid pharmacology: the first 66years. British Journal of Pharmacology 2006, 147(Suppl 1):163-S171.
126. Pertwee R.G. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: delta(9)-tetrahydrocannabinol, cannabidiol and delta(9)-tetrahydrocannabivarin. British Journal of Pharmacology 2007, 153(2):199-215.
127. Pessiglione M., Seymour B., Flandin G., et al. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006, 442:1042-1045.
128. Pilowsky L.S., Costa D.C., Ell P.J., et al. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. British Journal of Psychiatry 1994, 164:16-26.
129. Pistis M., Porcu G., Melis M., et al. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. The European Journal of Neuroscience 2001, 14:96-102.
130. Pistis M., Ferraro L., Pira L., et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Research 2002, 948:155-158.
131. Prasad B.M., Sorg B.A., Ulibarri C., et al. Sensitization to stress and psychostimulants. Involvement of dopamine transmission versus the HPA axis. Annals of the New York Academy of Sciences 1995, 771:617-625.
132. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188:425-444.
133. Riegel A.C., Lupica C.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. Journal of Neuroscience 2004, 24:11070-11078.
134. Robbe D., Kopf M., Remaury A., et al. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8384-8388.
135. Robinson T.E., Becker J.B. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro. European Journal of Pharmacology 1982, 85:253-254.
136. Ronesi J., Gerdeman G.L., Lovinger D.M. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. Journal of Neuroscience 2004, 24:1673-1679.
137. Schultz W. Predictive reward signal of dopamine neurons. Journal of Neurophysiology 1998, 80:1-27.
138. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
139. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (New York, N.Y.) 1987, 1:133-152.
140. Semple D.M., McIntosh A.M., Lawrie S.M. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology (Oxford, England) 2005, 19:187-194.
141. Shen W., Flajolet M., Greengard P., et al. Dichotomous dopaminergic control of striatal synaptic plasticity. Science (New York, N.Y.) 2008, 321:848-851.
142. Smith A., Li M., Becker S., et al. Dopamine, prediction error and associative learning: a model-based account. Network (Bristol, England) 2006, 17:61-84.
143. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. Journal of Psychiatry and Neuroscience 2007, 32:30-52.
144. Sorg B.A., Kalivas P.W. Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. Brain Research 1991, 559:29-36.
145. Stokes P.R., Mehta M.A., Curran H.V., et al. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage 2009, 48(1):186-190.
146. Stuber G.D., Klanker M., de Ridder B., et al. Reward-predictive cues enhance excitatory synaptic strength onto midbrain dopamine neurons. Science (New York, N.Y.) 2008, 321:1690-1692.
147. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (New York, N.Y.) 1997, 276:2048-2050.
148. Thiemann G., Di Marzo V., Molleman A., et al. The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology, Biochemistry and Behavior 2008, 89:384-391.
149. Thiemann G., van der Stelt M., Petrosino S., et al. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioral Brain Research 2008, 187:289-296.
150. van Os J., Bak M., Hanssen M., et al. Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 2002, 156:319-327.
151. Varvel S.A., Lichtman A.H. Evaluation of CB1 receptor knockout mice in the Morris water maze. The Journal of Pharmacology and Experimental Therapeutics 2002, 301:915-924.
152. Verrico C.D., Jentsch J.D., Roth R.H. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse (New York, N.Y.) 2003, 49:61-66.
153. Verrico C.D., Jentsch J.D., Roth R.H., et al. Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharmacology 2004, 29:522-529.
154. Voruganti L.N., Slomka P., Zabel P., et al. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research 2001, 107:173-177.
155. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987, 44:660-669.
156. Weiss S.M., Whawell E., Upton R., et al. Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation. Neurology 2003, 61:S88-S93.
157. Welch K.A., McIntosh A.M., Job D.E., et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophrenia Bulletin 2010, March 11. [Epub ahead of print].
158. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
159. Wilson W., Mathew R., Turkington T., et al. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. Journal of Addictive Diseases 2000, 19:1-22.
160. Yin H.H., Lovinger D.M. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8251-8256.
161. Yin H.H., Mulcare S.P., Hilario M.R., et al. Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nature Neuroscience 2009, 12:333-341.
162. Yucel M., Solowij N., Respondek C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 2008, 65:694-701.
163. Zammit S., Moore T.H., Lingford-Hughes A., et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 2008, 193:357-363.
164. Zuardi A., Crippa J., Hallak J., et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology 2008, 23(8):979-983.